Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alector Inc
(NQ:
ALEC
)
4.620
+0.400 (+9.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alector Inc
< Previous
1
2
Next >
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
September 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
August 29, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
August 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
July 31, 2024
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
July 28, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
July 23, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
June 10, 2024
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
May 09, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
February 28, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 27, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
February 20, 2024
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
February 08, 2024
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally
From
Alector, Inc.
Via
GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
February 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Closing of Public Offering
January 19, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Pricing of Public Offering of Common Stock
January 17, 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Proposed Public Offering of Common Stock
January 16, 2024
From
Alector, Inc.
Via
GlobeNewswire
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
November 28, 2023
Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the Stifel Healthcare Conference
November 08, 2023
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
October 27, 2023
From
Alector, Inc.
Via
GlobeNewswire
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
September 07, 2023
Data readout expected in Q4 2024
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
August 31, 2023
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
From
Alector, Inc.
Via
GlobeNewswire
Alector to Host Mid-Year Earnings Conference Call
July 27, 2023
Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT
From
Alector, Inc.
Via
GlobeNewswire
Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Alector, Inc.
Via
GlobeNewswire
Alector Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
Alector, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.